GBA's "2021 Stock Phantasma"

Baozun Inc. (BZUN)- Is this the bottom? Let me check with the Chinese Gov...Yes. $24
NasdaqGS - NasdaqGS Real Time Price. Currency in USD

24.050.00 (0.02%)
As of 11:43AM EDT.
 
Van-
Cerner up 1% after Betaville issues 'Uncooked Alert' 15:32 CERN Shares of Cerner are up 54c, or 1%, to $78.83 in afternoon trading after Ben Harrington's Betaville M&A site issued an "Uncooked Alert" regarding the name. Harrington defines an "Uncooked Alert" as "market gossip as Betaville receives it. This scuttlebutt has just come in and hasn't been checked with all of Betaville's well-informed RARE sources let alone formal journalistic channels (public relations executives, bankers etc). The rumour might be total codswallop, rubbish or nonsense - but then again there may be something in it, so it's worth airing on Betaville."

YEA BUT WHAT'S THE RUMOR!
 
a zig zag investment.


Turning Point Brands invests $8M in Old Pal Holding 07:38
TPB
Turning Point Brands announced that the company has completed a $8M strategic investment in Old Pal Holding. TPB invested in the form of a convertible note which includes additional follow-on investment rights. Old Pal is a brand in the cannabis space that operates a non-plant touching licensing model. The company sells its products and lifestyle goods across the U.S. with its multi-state approach. TPB's investment will enable Old Pal to expand product offerings in existing states, which include California, Nevada, Michigan, Oklahoma, Ohio, Washington and Massachusetts.

Turning Point Brands reports Q2 adjusted EPS 84c, consensus 65c 07:35 TPB Reports Q2 revenue $122.64M, consensus $106.22M. Gross profit increased 25.1% to $60M. "Our second quarter performance continued to demonstrate Turning Point's positive growth momentum, led by our core market segments. Zig-Zag had an exceptional quarter with over 70 percent growth, driven principally by our strategic initiatives and aided by a favorable comparison against a COVID-related disruption in MYO cigar wraps the previous year. Stoker's also delivered a solid quarter fueled by double-digit growth in our MST business," said Larry Wexler, president and CEO, Turning Point Brand
 
stonedinvestor said:
Folks I cannot believe what I am reading! - I need everybody in this stock the way Van is.

uniQure reports Q2 EPS $8.51, consensus $2.96 -:wtf:07:11 QURE Reports Q2 revenue $463.9M, consensus $190.02M. "We had a highly productive second quarter of this year marked by several notable achievements, including the closing on our global commercial licensing agreement with CSL Behring in hemophilia B and the recent presentation of 52-week data on all patients in our HOPE-B pivotal study showing durable and sustained increases in Factor IX levels within the non-hemophiliac range1, as well as significant reductions in both bleeding events and usage of replacement therapy after a one-time administration of etranacogene dezaparvovec," stated Matt Kapusta, chief executive officer at uniQure. "Additionally, we continued to make strong progress in our U.S. Phase I/II study of AMT-130 in Huntington's disease, including the completion of patient enrollment in the first dose cohort and the initiation of dosing in the second cohort. We also recently hosted a Research and Development Day where we disclosed four new promising research programs that complemented our expanding focus in neurological disease and larger patient populations, including the acquisition of Corlieve Therapeutics and its gene therapy program targeting temporal lobe epilepsy that builds on our expanding focus in serious neurological diseases," he added. "These investments deliver on our commitment to leverage our strong cash position to invest in new research programs and enabling technologies with the potential to drive significant value. In the second half of 2021, we expect to continue our progress across all programs, including availability of 78-week data from the HOPE-B study, initiating patient enrollment for our open-label European study of AMT-130 in Huntington's disease, and announcing initial data on the first four randomized Huntington's disease patients in the ongoing U.S. Phase I/II study."
More...

our girl livshits just did a write up on QURE:

"QURE (Buy): PT $95 on 2Q21 Updates; Will 2022 Catalysts Drive Value Inflection?"

if anyone can figure out how to access her reports please let me know. https://www.chardan.com/research
 
Our Girl Livshits? What a great name for a TV show! If she is from Chardan and if Chardan is an investment house... I can probably get the report through the HF.

QURE will be bought out I really think in the long run.

Hey what about pfizer. Nobody liked because A) We got this pandemic on the run and B) the shots were not big enough part of their business-- they were not a " pure play " on vaccine so nobody liked them. Really?

  • Citing the strength of its COVID-19 vaccine business, Pfizer(NYSE:PFE)has increased its revenue expectations for 2021 after second-quarter financials exceeded the analyst expectations.
  • Ahead of analyst expectations of $18.7B, the company recorded $19.0B in revenue for Q2 2021 indicating 86% YoY growth thanks to $7.8B sales recorded for the company’s COVID-19 vaccine co-developed with BioNTech(NASDAQ:BNTX).
  • Without the impact of the vaccine, revenue grew 10% YoY to $11.1B. The sales from the Prevnar franchise rose 34% YoY while the oncology business, the second biggest contributor to the top line grew 16% YoY. The adjusted diluted EPS rose 73% YoY to $1.05.
  • Compared to the previous projection of $70.5B-72.5B, Pfizer now estimates its 2021 revenue and adjusted EPS to be in the range of $78.0 – $80.0B and $3.95 – $4.05, respectively. The consensus estimates for 2021 revenue and EPS stood at$72.06B and $3.65, respectively.
  • Anticipating to deliver 2.1B doses in 2021 and manufacture up to 3B doses by the end of the year, the company now expects $33.5B in 2021 sales for the COVID-19 vaccine compared to previous estimates of $15B and $26.6B in the consensus.
First off expectations were huge $18.7B jesus how can you brat when the analysts are ramped up like that? Well they did-- taking a natural 10% growth and adding a whole bunch more...

now expects $33.5B in 2021 sales for the COVID-19 vaccine compared to previous estimates of $15B and $26.6B in the consensus.

Once again look at the frisky analyst estimates up at $26.6 vs the companies own $15 but Biden team just bought a huge amount and Pfizer now expects $33.5B in sales<---- Wow!

Pfizer is a buy.
 
You must log in or register to reply here.
Back
Top